Eli Lilly to spend billions on new pharmaceutical manufacturing sites
Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.
Eli Lilly says it will spend billions to move drug manufacturing to U.S. soil
Eli Lilly said Wednesday it will build three manufacturing plants in the United States to make the key raw ingredients in its medicines, a push to bring home a critical part of the pharmaceutical supply chain that largely comes from foreign sources.
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, shoring up domestic manufacturing as President Donald Trump threatens new tariffs on pharmaceuticals.
Eli Lilly plans to invest $27B to build four new US plants as tariffs loom
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.
Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target (CORRECTED)
The story has been updated to correct the new site locations At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States.
Indy-based pharmaceutical giant Eli Lilly to invest roughly $27 billion in manufacturing
Pharmaceutical giant Eli Lilly announced Wednesday that it plans to invest roughly $27 billion in United States manufacturing more than doubling its investment over the past five years. The company said this will be the largest pharmaceutical manufacturing investment in United States history.
Eli Lilly announces $27 billion investment in U.S. drug manufacturing sites
Eli Lilly plans to spend $27 billion to build new drug manufacturing sites in the U.S., at a time when President Trump is seeking to press drugmakers to move stateside.
Eli Lilly's big investment, cheaper Zepbound, and what's next for Hims & Hers: Pharma news roundup
Eli Lilly announced plans to invest $27 billion in four new manufacturing sites in the United States. The pharma giant also made a wider range of doses of its blockbuster weight-loss drug Zepbound available in vials and at lower prices.
Eli Lilly Expands IN, NC, WI Sites, Invests $50B In U.S. Since 2020
The pharmaceutical firm is growing its presence across three states, creating 3,000 jobs.
Eli Lilly plans to more than double investment in US manufacturing
The Indianapolis-based pharmaceutical company announced plans for four new manufacturing sites, but has not decided where they will go.
Eli Lilly wants to make drugs in America. First it wants a tax cut
Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday that it plans to invest $27 billion in four new manufacturing sites in the United States. But the company made it clear that those plans hinge on tax cuts.
Yen on MSN2d
Eyeing Trump trade policy shakeup, Eli Lilly to build 4 US factories
US pharmaceutical giant Eli Lilly announced Wednesday that it will build four additional new manufacturing sites in the ...
Eli Lilly in pact with Magnet Bio to develop cancer drugs in a deal worth up to $1.25B
Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's ...
MM&M16h
Faced with compounded drugs, Eli Lilly tells consumers to ‘be a healthy skeptic’
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.